NeurAxis Stock Price, News & Analysis (NASDAQ:NRXS) $3.26 +0.26 (+8.67%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$2.25▼$3.3650-Day Range$1.90▼$4.1852-Week Range$1.80▼$6.93Volume49,470 shsAverage Volume40,835 shsMarket Capitalization$17.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media About NeurAxis Stock (NASDAQ:NRXS)NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.Read More NRXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXS Stock News HeadlinesNovember 21, 2023 | finanznachrichten.deNeurAxis, Inc.: NeurAxis Reports Third Quarter 2023 Financial ResultsNovember 21, 2023 | msn.comNeurAxis reports Q3 resultsNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 20, 2023 | finance.yahoo.comNeurAxis Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | finance.yahoo.comNeurAxis Announces CareFirst BCBS Policy CoverageNovember 14, 2023 | msn.comNeurAxis secures $3M financing through preferred stock offeringNovember 14, 2023 | finance.yahoo.comNeurAxis Secures $3 Million FinancingNovember 8, 2023 | finance.yahoo.comNeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal DeviceNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 5, 2023 | morningstar.comNeuraxis Inc NRXS Stock QuoteSeptember 26, 2023 | finance.yahoo.comNeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain DisordersSeptember 21, 2023 | finance.yahoo.comNeurAxis Reports Second Quarter 2023 Financial ResultsSeptember 13, 2023 | finance.yahoo.comNeurAxis to Present at the Gilmartin Group Emerging Growth ShowcaseSeptember 12, 2023 | stockhouse.comNeurAxis Announces Publication of Prospective Study Showing IB-Stim(TM) Improves Quality of Life of Adolescents with IBSSeptember 12, 2023 | msn.comEXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel SyndromeSeptember 12, 2023 | finance.yahoo.comNeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBSSeptember 8, 2023 | finance.yahoo.comNeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz WisconsinSeptember 8, 2023 | finance.yahoo.comExchange Listing Client, Neuraxis, Inc., Successfully Completes Its Initial Public Offering and NYSE ListingSeptember 8, 2023 | finance.yahoo.comGoldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.September 8, 2023 | finance.yahoo.comNeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023September 8, 2023 | finance.yahoo.comNeurAxis Announces Over $8 Million in IB-Stim™ RevenueSeptember 8, 2023 | finance.yahoo.comNeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut MicrobiomeSeptember 8, 2023 | finance.yahoo.comNeurAxis Highlights Strength of its Board of DirectorsSeptember 8, 2023 | finance.yahoo.comNeurAxis Highlights Pediatric Post-Concussion Clinical StudySee More Headlines Receive NRXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/21/2023Today11/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NRXS CUSIPN/A CIK1933567 Webneuraxis.com Phone(812) 689-0791FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.68 million Price / Sales5.92 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,290,000Free FloatN/AMarket Cap$15.87 million OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Brian Carrico (Age 41)President, CEO & Director Comp: $373.58kDr. Adrian Miranda (Age 53)Chief Medical Officer, Senior VP of Science & Technology and Director Comp: $266.35kMr. Thomas Carrico (Age 66)Chief Regulatory Officer & Director Comp: $287.2kMr. Christopher Robin Brown D.D.S. (Age 69)Founder, Director of Innovation & Director Mr. Gary Peterson (Age 57)Founder, Director of Design & Engineering and Director Mr. John G. Seale CPA (Age 63)CFO & Teasurer Mr. Dan Clarence (Age 63)COO & Director More ExecutivesKey CompetitorsHelius Medical TechnologiesNASDAQ:HSDTPrecision OpticsNASDAQ:POCIVivani MedicalNASDAQ:VANIMovanoNASDAQ:MOVENocturne AcquisitionNASDAQ:MBTCView All CompetitorsInstitutional OwnershipStifel Financial CorpBought 25,710 shares on 11/13/2023Ownership: 0.516%View All Institutional Transactions NRXS Stock Analysis - Frequently Asked Questions Should I buy or sell NeurAxis stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeurAxis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NRXS shares. View NRXS analyst ratings or view top-rated stocks. How have NRXS shares performed in 2023? NeurAxis' stock was trading at $6.00 at the beginning of 2023. Since then, NRXS stock has decreased by 45.7% and is now trading at $3.26. View the best growth stocks for 2023 here. How were NeurAxis' earnings last quarter? NeurAxis, Inc. (NASDAQ:NRXS) issued its earnings results on Thursday, September, 21st. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.99. The business had revenue of $0.65 million for the quarter. When did NeurAxis IPO? (NRXS) raised $7 million in an initial public offering on Wednesday, August 9th 2023. The company issued 1,098,667 shares at a price of $6.00 per share. Who are NeurAxis' major shareholders? NeurAxis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (0.52%). How do I buy shares of NeurAxis? Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NRXS) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.